DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02898506

CompletedPhase 2

Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Lead sponsor

University of Oulu

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

4

Recruiting sites

—

Enrollment

13

actual

Study population

Prediabetes / glucose intolerance, Type 1 diabetes

Key I/E criterion

•HbA1c 2-12%

Primary endpoint

•FPIR

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02898506
Org study IDLiraAABDG10-30
Secondary ID2014-004761-25
Secondary IDU1111-1177-0704WHO

Timeline

Milestones

Study first posted2016-09-13estimated
Last update posted2022-01-25actual
Study start2016-03actual (month precision)
Primary completion2021-06actual (month precision)
Study completion2021-06actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Prediabetes / glucose intoleranceType 1 diabetes

Eligibility

Who can enroll

Minimum age10 Years
Maximum age30 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•10-30 years of age
•positive for at least 2 islet autoantibodies
•glucose intolerance or dysglycemia: impaired glucose tolerance (IGT, 2-hour p-gluc 7.8-11.0mmol/l), or impaired fasting glucose (IFG, fp-gluc 6.1-6.9mmol/l), and/or 10% rise in HbA1c since the last measurement (2 - 12 mo ago), and/or p-gluc at least 11.1mmol/l at 30, 60 or 90 min during OGTT
•not pregnant

Exclusion criteria

•allergic to liraglutide or other ingredients of Victoza
•type 1 diabetes
•diabetic ketoacidosis
•previous treatment in the last three months with any antidiabetic medication
•impaired liver or kidney function or on dialysis
•severe heart failure
•severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease
•past or current history of pancreatitis
•serum calcitonin value above normal (>50 ng/l or at least 3.4pmol/l)
•presence of any chronic metabolic, hematologic or malignant disease
•obesity BMI at least 30
•pregnant females and females of childbearing potential who are not using adequate contraceptive methods.
•breast-feeding

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Safety / tolerability / PK
2

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint/low confidence

FPIR (1+3min serum insulin level after iv glucose infusion)

Time frame:12 months

descriptive

Secondary/protocol endpoint

Serum C-peptide AUC

Time frame:12 months

C-peptide AUC

concentration, descriptive

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint/low confidence

Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia

Time frame:12 months

descriptive

componentsamylase serum, amylase urine, lipase serum, calcitonin serum, hypoglycemia

Secondary/protocol endpoint

Tolerability

Time frame:12 months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.